Wegovy works. The clinical data is clear on that. But at roughly $1,300 per month at retail, the cost question hits just as fast as the effectiveness question for most people. Whether your insurance covers Wegovy depends on your specific plan, your diagnosis, and in some cases, your employer. Here’s what you actually need to know to figure out where you stand.<\/p>\n
Wegovy is the brand name for semaglutide 2.4 mg, manufactured by Novo Nordisk and FDA-approved specifically for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity like hypertension, type 2 diabetes, or high cholesterol.<\/p>\n
The FDA approval happened in 2021, which should in theory make coverage more straightforward. The complication is that insurance coverage for weight loss medications in the United States has historically been inconsistent and, in many cases, explicitly excluded. Many employer-sponsored health plans carved out obesity medications as a benefit category long before GLP-1s existed, and updating those exclusions requires deliberate action by employers and insurers.<\/p>\n
The result is a patchwork: some plans cover Wegovy with manageable cost-sharing, others exclude it entirely, and many fall somewhere in between with prior authorization requirements that can take weeks to navigate.<\/p>\n
Coverage varies significantly by plan type.<\/p>\n
Commercial employer-sponsored plans<\/strong> are the most variable. Some large employers have added Wegovy coverage proactively, particularly after clinical data on cardiovascular benefits emerged. Others maintain blanket exclusions for weight loss medications. Your human resources department or plan documents are the fastest way to find out where your employer stands.<\/p>\n Medicare<\/strong> does not currently cover Wegovy for weight loss alone. This has been a point of policy debate, and there is ongoing legislative effort to change it, but as of now Medicare Part D excludes weight loss medications by statute. There is a narrow exception for patients with established cardiovascular disease following the SELECT trial results, but coverage remains limited.<\/p>\n Medicaid<\/strong> coverage varies by state. Some states have added GLP-1 coverage for obesity, others have not. Checking your state’s Medicaid formulary is the only reliable way to know.<\/p>\n ACA marketplace plans<\/strong> are not required to cover obesity medications, and many don’t. Some do, particularly at higher metal tiers, but it’s not guaranteed.<\/p>\n Even when your plan covers Wegovy, prior authorization is almost always required. This means your prescribing provider needs to submit documentation to your insurance company before coverage kicks in. The process typically requires:<\/p>\n A confirmed diagnosis of obesity (BMI of 30 or higher) or overweight with comorbidities. Documentation of previous weight loss attempts through diet, exercise, or other interventions. Confirmation that Wegovy is being prescribed for an approved indication. In some cases, a requirement that other interventions have been tried and failed first.<\/p>\n Prior authorization requests can take anywhere from a few days to several weeks. Denials are common on the first submission and can be appealed. If your provider’s office has experience with GLP-1 prior authorizations, the process tends to go more smoothly.<\/p>\n A denial isn’t necessarily the end of the road. Here’s the practical sequence worth following:<\/p>\n Request an explanation of the denial.<\/strong> Insurance companies are required to provide a reason. Common reasons include the medication being excluded from the formulary, missing documentation, or a determination that criteria weren’t met.<\/p>\n Ask your provider to file an appeal.<\/strong> If the denial was based on missing documentation or a coverage criteria dispute, an appeal with supporting clinical notes and medical necessity documentation has a reasonable chance of success. Providers who prescribe GLP-1 medications regularly often have staff experienced in this process.<\/p>\n Check for a formulary exception.<\/strong> If semaglutide is covered under a different brand name or indication on your plan, your provider may be able to request a formulary exception.<\/p>\n Request a peer-to-peer review.<\/strong> Your provider can request a direct conversation with the insurance company’s medical reviewer. This is underused and sometimes effective, particularly when there’s strong clinical documentation supporting the prescription.<\/p>\n For a broader look at navigating insurance and cost barriers across GLP-1 medications, how to get GLP-1 medications without insurance<\/a> covers the full range of alternative pathways.<\/p>\n For patients with commercial insurance that covers Wegovy, Novo Nordisk offers a savings card that can reduce out-of-pocket costs significantly, in some cases to as low as $0 per month for eligible patients. This program is not available for patients on Medicare, Medicaid, or other government-funded insurance.<\/p>\n Eligibility and savings amounts change periodically, so checking directly with Novo Nordisk or through your pharmacy is the most reliable way to confirm current terms.<\/p>\n If your insurance doesn’t cover Wegovy and appeals haven’t worked, you’re not out of options. The most cost-effective alternative for most patients is compounded semaglutide through a licensed telehealth provider.<\/p>\n Compounded semaglutide contains the same active ingredient as Wegovy and is prescribed at clinically equivalent doses, but it’s prepared by compounding pharmacies rather than manufactured by Novo Nordisk. This distinction removes the brand-name pricing, making monthly costs significantly more accessible.<\/p>\n Through TrimRx, compounded semaglutide starts at a fraction of the brand-name retail price. The compounded semaglutide product page<\/a> has current pricing, and the process involves an online consultation rather than an in-person visit.<\/p>\n It’s worth noting that the FDA has taken a position on compounded semaglutide availability that has evolved over time, and the regulatory landscape for compounded GLP-1 medications is worth discussing with your provider to understand current options.<\/p>\n Some patients find that Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg, approved for type 2 diabetes) is covered by their plan even when Wegovy isn’t. This happens because coverage for diabetes medications is more consistently included in formularies than coverage for weight loss medications, even when the active ingredient is the same.<\/p>\n If you have type 2 diabetes or prediabetes alongside obesity, your provider may be able to prescribe Ozempic for the diabetes indication with weight loss as a secondary benefit. This is a clinical and coverage decision your provider needs to make based on your specific diagnosis and plan rules.<\/p>\nPrior Authorization: What to Expect<\/h2>\n
What to Do If Your Insurance Denies Coverage<\/h2>\n
The Novo Nordisk Savings Program<\/h2>\n
When Insurance Won’t Cover It: Alternatives Worth Knowing<\/h2>\n
Wegovy vs Ozempic: Does the Insurance Distinction Matter?<\/h2>\n